Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Thrombogenics NV (OTC: TBGNF).

Full DD Report for TBGNF

You must become a subscriber to view this report.

Recent News from (OTC: TBGNF)

Oxurion and Beta Therapeutics to Develop New Heparanase Inhibitors for Treatment of dry AMD
LEUVEN, Belgium , November 5, 2018 /PRNewswire/ -- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that it entered into a strategic research col...
Source: PR Newswire
Date: November, 05 2018 11:40
Oxurion NV Announces the Appointment of Adrienne Graves to Its Board of Directors
LEUVEN, Belgium , October 29, 2018 /PRNewswire/ -- Oxurion NV  (Euronext Brussels: OXUR -  formerly known as ThromboGenics   NV ), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, ann...
Source: PR Newswire
Date: October, 29 2018 02:30
ThromboGenics becomes Oxurion
ThromboGenics NV ( OTCPK:TBGNF ) changes the name of the company to "Oxurion NV". The change will be implemented in the next days and weeks. More news on: Thrombogenics NV, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: September, 04 2018 07:23
ThromboGenics plans name change to "Oxurion"
ThromboGenics NV ( OTCPK:TBGNF )  announces its intention to change its name to “Oxurion NV”. More news on: Thrombogenics NV, Read more ...
Source: SeekingAlpha
Date: June, 27 2018 09:27
ThromboGenics enrolls first patient in Phase 1 clinical study evaluating THR-149 for treatment of DME
ThromboGenics NV ( OTCPK:TBGNF ) has enrolled  first patient in a Phase 1 open-label, dose escalation study evaluating the safety of THR-149 in the treatment of Diabetic Macular Edema (DME). More news on: Thrombogenics NV, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 25 2018 07:40
ThromboGenics commences mid-stage study of THR-317/Lucentis combo in DME
Enrollment in underway in a Phase 2 clinical trial evaluating ThromboGenics NV's ( OTCPK:TBGNF ) THR-317, combined with Novartis' ( NVS +0.1% ) Lucentis (ranibizumab) in patients with diabetic macular edema (DME). More news on: Thrombogenics NV, Novartis AG, Healthcare stocks news, ...
Source: SeekingAlpha
Date: April, 27 2018 12:40
FDA OKs AI software to detect diabetic retinopathy
Under its De Novo (no predicate product) review pathway, the FDA approves the first medical device in the U.S. that uses artificial intelligence (AI) to perform its designated function. The device, called IDx-DR, is a software program used to detect greater than a mild level of diabetic re...
Source: SeekingAlpha
Date: April, 11 2018 12:51
Your Daily Pharma Scoop: Celgene Upside, Erytech Tumbles, Novartis Neulasta Biosimilar
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea...
Source: SeekingAlpha
Date: December, 11 2017 07:00
ThromboGenics discontinues patient enrolment in Phase II CIRCLE study evaluating THR-409 for NPDR due to slow recruitment rate
ThromboGenics NV ( OTCPK:TBGNF ) announces that it has discontinued patient recruitment in its Phase 2 CIRCLE study for Non-Proliferative Diabetic Retinopathy (NPDR), effective immediately, due to the trial's slow recruitment rate. More news on: Thrombogenics NV, Healthcare stocks news, ...
Source: SeekingAlpha
Date: December, 08 2017 07:32


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TBGNF.

About Thrombogenics NV (OTC: TBGNF)

Logo for Thrombogenics NV (OTC: TBGNF)

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company s lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion VMA . The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re submitted in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.


Contact Information



Current Management

  • Patrik De Haes / CEO
  • Luc Philips / CFO

Current Share Structure

  • Market Cap: $162,879,144 - 03/09/2018
  • Issue and Outstanding: 32,413,760 - 06/30/2011


Daily Technical Chart for (OTC: TBGNF)

Daily Technical Chart for (OTC: TBGNF)

Stay tuned for daily updates and more on (OTC: TBGNF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TBGNF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TBGNF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TBGNF and does not buy, sell, or trade any shares of TBGNF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: